Avidity Biosciences Q4 EPS $(0.79) Misses $(0.66) Estimate, Sales $2.19M Down From $2.77M YoY
Portfolio Pulse from Happy Mohamed
Avidity Biosciences reported a Q4 EPS of $(0.79), missing the $(0.66) estimate, with sales of $2.19M, down 20.80% YoY from $2.77M.
February 28, 2024 | 9:44 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Avidity Biosciences reported a larger than expected quarterly loss and a decrease in sales compared to last year.
The reported earnings miss and year-over-year sales decrease are likely to negatively impact investor sentiment and could lead to a short-term decrease in stock price. The significant miss on the EPS estimate and the substantial decrease in sales highlight potential operational challenges.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100